<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hereditary neuropathies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hereditary neuropathies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hereditary neuropathies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter B Kang, MD, FAAP, FAAN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defect, and subsequently upon specific genetic loci. The primary hereditary neuropathies predominantly or exclusively affect peripheral nerves and produce symptoms of peripheral nerve dysfunction. Other hereditary neuropathies affect both the central and peripheral nervous systems and, in some cases, other organs; in such patients, symptoms related to the peripheral neuropathy may be overshadowed by other manifestations of the disease.</p><p>This topic will provide an overview of the hereditary neuropathies. Hereditary disorders that may cause peripheral neuropathy along with systemic symptoms and/or central nervous system dysfunction are discussed separately. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders"</a>.)</p><p>Nonhereditary acquired neuropathies are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5282.html" rel="external">"Overview of upper extremity peripheral nerve syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5278.html" rel="external">"Overview of lower extremity peripheral nerve syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14174.html" rel="external">"Immune-mediated neuropathies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5275.html" rel="external">"Epidemiology and classification of diabetic neuropathy"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Historically, the primary hereditary neuropathies were designated by eponyms that had the connotation of specific clinical features (eg, Charcot-Marie-Tooth [CMT] disease or Dejerine-Sottas disease). However, phenotypic variability resulted in substantial diagnostic confusion. What became known as the Dyck classification was proposed in 1968, based upon clinical and electrophysiologic features [<a href="#rid1">1</a>], and the inherited neuropathies with primarily motor and sensory manifestations became known as the hereditary motor sensory neuropathies (HMSNs). However, the popularity of the CMT eponym for the HMSNs has had a resurgence since the 1990s, especially as a more comprehensive classification tree based on associated genes has been built upon the original broad CMT categories that were based largely on inheritance patterns and neurophysiology.</p><p class="bulletIndent1"><span class="glyph">●</span>Many of the primary hereditary neuropathies are divided into motor-sensory (CMT) and sensory-autonomic neuropathies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The motor-sensory category was subdivided into types 1 through 7 and the sensory neuropathies into types 1 through 5. Many of these types were further divided into subcategories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional primary inherited neuropathies not included in this classification include hereditary neuropathy with pressure palsy, hereditary brachial plexopathy, and giant axonal neuropathy. The molecular defects in many of the inherited neuropathies have been identified.</p><p></p><p>The accelerating pace of genetic discoveries has identified a broadening phenotypic spectrum associated with specific genetic pathogenic variants and revealed an increasing degree of genetic heterogeneity and clinical overlap among the major categories of inherited neuropathies [<a href="#rid2">2,3</a>]. As an example, a pathogenic variant in the <em>KIF5A</em> gene can cause either an isolated axonal neuropathy (CMT2) phenotype or a type of hereditary spastic paraplegia (HSP) characterized by leg spasticity and weakness due to upper motor neuron involvement and often associated with an axonal neuropathy [<a href="#rid2">2,4</a>]. (See  <a class="medical medical_review" href="/d/html/14152.html" rel="external">"Hereditary spastic paraplegia", section on 'Autosomal dominant HSP'</a>.)</p><p>As genetic discoveries continue to unfold, traditional classifications of hereditary neurologic diseases are likely to be superseded by classifications based primarily upon the underlying genetic cause.</p><p class="headingAnchor" id="H3"><span class="h1">CHARCOT-MARIE-TOOTH DISEASE</span><span class="headingEndMark"> — </span>Charcot-Marie-Tooth (CMT) is a spectrum of disorders caused by specific pathogenic variants in genes that are typically expressed in myelin and/or axons. Most CMT cases are associated with pathogenic variants in one of four genes: <em>PMP22</em>,<em> MPZ</em>,<em> GJB1</em>, and <em>MFN2</em> [<a href="#rid5">5</a>]. </p><p>The clinical expression of these conditions is often affected by "gene dosage imbalance" caused by DNA duplications or deletions, as is the case in the most common form of CMT (ie, CMT1A caused by <em>PMP22</em> gene duplications). The association of different pathogenic variants within the same gene with various clinical phenotypes is a common finding in the HMSN/CMT group of peripheral neuropathies. This variability suggests that these disorders represent a spectrum of related phenotypes caused by an underlying defect in peripheral nervous system myelination and/or axonal function.</p><p class="headingAnchor" id="H4058953453"><span class="h2">CMT subtypes</span><span class="headingEndMark"> — </span>CMT has been classified as types 1 through 7 based on clinical, neurophysiologic, and inheritance patterns. There are currently over 50 genetic subtypes of CMT [<a href="#rid6">6</a>]. The majority of cases fall within type 1 (autosomal dominant inheritance, demyelinating physiology) and type 2 (autosomal dominant inheritance, axonal physiology), with an estimated prevalence of 10 per 100,000 in Belgrade, Serbia [<a href="#rid7">7</a>] and 35 per 100,000 in Finland [<a href="#rid8">8</a>]. Common features include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits  (<a class="graphic graphic_table graphicRef72688" href="/d/graphic/72688.html" rel="external">table 1</a>).</p><p>A distinct complication observed in some patients with X-linked CMT type 1 (CMTX1) involves transient episodes of dysarthria, ataxia, hemiparesis, or tetraparesis, associated with similarly transient white matter lesions in the brain [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/6220.html" rel="external">"Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'CMTX1'</a>.)</p><p class="headingAnchor" id="H431556925"><span class="h2">Hereditary neuropathy with liability to pressure palsy</span><span class="headingEndMark"> — </span>Hereditary neuropathy with liability to pressure palsy (HNPP, tomaculous neuropathy) is a recurrent, episodic demyelinating neuropathy  (<a class="graphic graphic_table graphicRef61436" href="/d/graphic/61436.html" rel="external">table 2</a>) associated with <em>PMP22</em> deletions and single nucleotide variants (SNVs) that is allelic to Charcot-Marie-Tooth disease type 1A (CMT1A) [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/6220.html" rel="external">"Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'Hereditary neuropathy with liability to pressure palsy'</a>.)</p><p>Affected patients typically present with isolated nerve palsies with localization in areas frequently affected by compression or trauma. The most frequently affected nerves include the axillary, median, radial, ulnar, peroneal, or brachial plexus nerves. Other findings include cranial nerve involvement, nerve deafness, and scoliosis.</p><p>Symptoms first appear in the second decade in most patients, but they can occur in younger children or be delayed into the third decade. Single nerve palsies typically appear sequentially, resolving in days to months, and may be associated with persistent motor deficits in the same or in another distribution.</p><p>HNPP is an autosomal dominant disorder. In approximately 80 percent of HNPP cases, there is a 1.5 Mb deletion in chromosome 17p11.2 that results in reduced expression of the <em>PMP22</em> gene. The deletion corresponds to the duplicated region of <em>PMP22</em> present in CMT1A (see  <a class="medical medical_review" href="/d/html/6220.html" rel="external">"Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'CMT1A'</a>). Approximately 20 percent of patients with HNPP have SNVs or small deletions in the <em>PMP22</em> gene, and sporadic cases with de novo deletions have been described.</p><p>CMT is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6220.html" rel="external">"Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/113945.html" rel="external">"Charcot-Marie-Tooth disease: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">HEREDITARY BRACHIAL PLEXOPATHY</span><span class="headingEndMark"> — </span>Hereditary brachial plexopathy is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies [<a href="#rid11">11</a>]. The condition is also known as hereditary neuralgic amyotrophy (HNA) and is caused by pathogenic variants in the <em>SEPT9</em> gene. Hereditary brachial plexopathy is distinct from hereditary neuropathy with predisposition to pressure palsies (HNPP) discussed above  (<a class="graphic graphic_table graphicRef61436" href="/d/graphic/61436.html" rel="external">table 2</a>). Childhood onset of hereditary brachial plexopathy is not unusual.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Many patients exhibit a relapsing-remitting course characterized by attacks that resolve spontaneously, either completely or incompletely, leaving additive residual weakness. The disorder can also follow a progressive pattern. Physical exertion and pregnancy are reported triggering events.</p><p></p><p class="bulletIndent1">Attacks are heralded by pain and paresthesias, followed by paresis of the shoulder and arm. While any nerve in the brachial plexus can be involved, injury to the upper part of the brachial plexus is most frequent. Characteristic somatic features of hereditary brachial plexopathy include short stature, hypotelorism, a small face, unusual skin folds, and creases on the neck.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Brachial plexopathy is diagnosed by clinical features of recurrent symptoms, supportive family history, and electrodiagnostic testing showing prolonged motor conduction latencies. </p><p></p><p>Hereditary brachial plexopathy is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5266.html" rel="external">"Brachial plexus syndromes", section on 'Hereditary brachial plexopathy'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">HEREDITARY SENSORY AND AUTONOMIC NEUROPATHIES</span><span class="headingEndMark"> — </span>Hereditary sensory and autonomic neuropathies (HSANs) occur much less frequently than do the primary hereditary motor sensory neuropathies. The major feature of these conditions is loss of large myelinated and unmyelinated fibers. They have been categorized into types 1 through 8, though there are multiple subtypes for some of these, leading to a total of at least 15 associated genes [<a href="#rid12">12</a>]. Some children do not fit well into the classification scheme  (<a class="graphic graphic_table graphicRef67377" href="/d/graphic/67377.html" rel="external">table 3</a>). The five classic types are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>HSAN type 1 is the most common form of HSAN and is inherited as an autosomal dominant disorder in most cases. It is characterized by degeneration of dorsal root ganglion and motor neurons, leading to distal sensory loss and later distal muscle wasting and weakness and variable neural deafness. Bone necrosis and spontaneous distal amputation can occur. Symptoms may begin in early childhood but can be delayed until the third decade. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN1'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms in HSAN type 2 are caused also by loss of pain, temperature, pressure and touch sensation with large and small fiber sensory involvement. Fractures and recurrent infections of the digits occur in early childhood, and mutilation of the fingers and toes occurs as the disease progresses. A stable, nonprogressive congenital form also has been recognized. HSAN2 is inherited in a recessive manner. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HSAN type 3 is more commonly known as Riley-Day syndrome or familial dysautonomia. This recessive disorder is a progressive sensorimotor neuropathy, but sympathetic autonomic dysfunction is responsible for most clinical manifestations. Neuropathic symptoms include loss of reflexes, hypotonia, and decreased perception of pain and temperature. Sympathetic symptoms include orthostatic hypotension, swallowing dysfunction, gastrointestinal motility dysfunction, bladder dysfunction, decreased or absent tearing, pupil dilation, decreased sweating (leading to defective temperature dysregulation), and blotchy skin. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN3 (Familial dysautonomia)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HSAN type 4, also called congenital insensitivity to pain with anhidrosis (CIPA), is an autosomal recessive disorder. Symptoms begin early in infancy and prominent features include profound loss of pain sensitivity, leading to injuries, self-mutilation, and osteomyelitis, episodic hyperthermia that can be associated with seizures, and mild to moderate intellectual disability. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN4'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HSAN type 5 disease have loss of pain and temperature sensation, but other sensation is preserved. It is an autosomal recessive disorder. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN5'</a>.)</p><p></p><p>HSANs are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">GIANT AXONAL NEUROPATHY</span><span class="headingEndMark"> — </span>Giant axonal neuropathy (GAN; also called giant axonal neurodegeneration) is a severe neurodegenerative disorder of the peripheral and central nervous system that becomes clinically apparent in early childhood [<a href="#rid13">13,14</a>]. It is transmitted as an autosomal recessive trait [<a href="#rid15">15</a>]. The disease locus maps to 16q24.1 [<a href="#rid16">16</a>], and the variant <em>GAN</em> gene encodes for a cytoskeletal protein called gigaxonin [<a href="#rid17">17</a>]. Abnormal gigaxonin is presumed to be responsible for the generalized disorganization of cytoskeletal intermediate filaments [<a href="#rid17">17-20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Affected children present with a gait disturbance and frequent falls caused by muscle weakness and ataxia [<a href="#rid14">14</a>]. There is a mixed motor sensory polyneuropathy with associated predominantly distal limb weakness [<a href="#rid21">21,22</a>]. A characteristic physical appearance is a hallmark of the disorder. The hair tends to be red and tightly curled, the forehead high, the complexion pale, and eyelashes long.</p><p></p><p class="bulletIndent1">Manifestations of central nervous system involvement include cerebellar dysfunction (eg, ataxia, dysmetria, oculomotor apraxia, and nystagmus), spasticity, and optic atrophy [<a href="#rid23">23,24</a>]. Intellectual disability occurs in some cases. Progressive gait deterioration occurs, with death usually by the third decade, most often due to respiratory failure [<a href="#rid14">14</a>]. A milder form of the disease resembling Charcot-Marie-Tooth disease has also been described [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrodiagnostic findings</strong> – Nerve conduction studies are consistent with an axonal neuropathy. Electroencephalograms, visual evoked potentials, and somatosensory evoked responses may be abnormal [<a href="#rid14">14,24</a>]. In some cases, brain magnetic resonance imaging (MRI) is normal [<a href="#rid14">14</a>], while in other cases MRI demonstrates subcortical, periventricular and cerebellar white matter lesions [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is suggested by findings on nerve biopsy and confirmed by genetic testing for pathogenic variants in the <em>GAN</em> gene [<a href="#rid14">14</a>]. Nerve biopsy shows axonal loss and distortion of fibers by giant axonal swellings filled with densely packed bundles of neurofilaments [<a href="#rid19">19,26,27</a>]. Similar filaments are seen in other tissues such as Schwann cells, fibroblasts, and vascular endothelium, findings that are consistent with a defect in intermediate filament organization [<a href="#rid19">19</a>]. Neuropathologic findings include degeneration of central tracts [<a href="#rid14">14</a>]. Cerebral white matter shows leukoencephalopathy, and the cerebellum and optic tracts show atrophy with gliosis.</p><p></p><p class="headingAnchor" id="H18"><span class="h1">NEUROPATHIES ASSOCIATED WITH GENERALIZED DISORDERS</span><span class="headingEndMark"> — </span>Several generalized hereditary disorders are associated with neuropathy. Many of these disorders affect both the central and peripheral nervous systems and, in some cases, other organs. Symptoms related to the peripheral neuropathy may be overshadowed by other manifestations of the disease. A partial list of systemic disorders that may produce a neuropathy includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Infantile neuroaxonal dystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Tangier disease</p><p class="bulletIndent1"><span class="glyph">●</span>Abetalipoproteinemia</p><p class="bulletIndent1"><span class="glyph">●</span>Refsum disease</p><p class="bulletIndent1"><span class="glyph">●</span>Chediak-Higashi syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary tyrosinemia.</p><p></p><p>In addition, neuropathy may occur with several other disorders associated with abnormalities of specific subcellular structures, such as lysosomes, mitochondria, and DNA. They may produce multiorgan symptoms and/or neurodegenerative features. Conditions that feature neuropathy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal diseases</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fabry disease</p><p class="bulletIndent2"><span class="glyph">•</span>Krabbe disease</p><p class="bulletIndent2"><span class="glyph">•</span>Metachromatic leukodystrophy</p><p class="bulletIndent2"><span class="glyph">•</span>Niemann-Pick disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Leigh syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Leber hereditary optic neuropathy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DNA repair disorders</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Xeroderma pigmentosum</p><p class="bulletIndent2"><span class="glyph">•</span>Cockayne syndrome</p><p></p><p>The neuropathies associated with these generalized metabolic disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders"</a>.)</p><p class="headingAnchor" id="H22289786"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83812.html" rel="external">"Patient education: Charcot-Marie-Tooth disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10539093"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Charcot-Marie-Tooth disease </strong>– Charcot-Marie-Tooth disease (CMT; also known as hereditary motor and sensory neuropathy) is a spectrum of disorders caused by pathogenic variants in genes that are expressed in myelin and/or axons. The vast majority of CMT cases are associated with pathogenic variants in one of four genes: <em>PMP22</em>, <em>MPZ</em>, <em>GJB1</em>, and <em>MFN2</em>. CMT has been classified as types 1 through 7 and includes over 50 different genetic subtypes  (<a class="graphic graphic_table graphicRef72688" href="/d/graphic/72688.html" rel="external">table 1</a>). (See <a class="local">'Charcot-Marie-Tooth disease'</a> above.)</p><p></p><p class="bulletIndent1">The most common CMT categories are CMT1 and CMT2, which together are the most frequent hereditary peripheral neuropathies. Shared features of CMT1 and CMT2 include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary neuropathy with liability to pressure palsy </strong>– Hereditary neuropathy with liability to pressure palsy (HNPP), a recurrent, episodic demyelinating neuropathy  (<a class="graphic graphic_table graphicRef61436" href="/d/graphic/61436.html" rel="external">table 2</a>), is allelic to CMT1A. Affected patients typically present with isolated nerve palsies in areas frequently affected by compression or trauma including the axillary, median, radial, ulnar, peroneal, or brachial plexus nerves. Single nerve palsies typically appear sequentially, resolving in days to months, and may be followed by persistent motor deficits in the same or in another distribution. (See <a class="local">'Hereditary neuropathy with liability to pressure palsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary brachial plexopathy </strong>– Hereditary brachial plexopathy is a rare autosomal dominant disorder characterized by recurrent, painful brachial plexopathies  (<a class="graphic graphic_table graphicRef61436" href="/d/graphic/61436.html" rel="external">table 2</a>). Attacks may be triggered by physical exertion and are heralded by pain and paresthesias, followed by paresis of the shoulder and arm. Many patients exhibit a relapsing-remitting course characterized by attacks that resolve spontaneously, either completely or incompletely, leaving additive residual weakness. (See <a class="local">'Hereditary brachial plexopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary sensory autonomic neuropathies </strong>– Hereditary sensory autonomic neuropathies (HSANs) are a rare group of conditions characterized by degeneration of dorsal root ganglion and motor neurons, leading to distal sensory loss and later distal muscle wasting and weakness and variable neural deafness. Bone necrosis and spontaneous distal amputation can also occur. They have been categorized into types 1 through 8, although some children do not fit well into this classification  (<a class="graphic graphic_table graphicRef67377" href="/d/graphic/67377.html" rel="external">table 3</a>). (See <a class="local">'Hereditary sensory and autonomic neuropathies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Giant axonal neuropathy </strong>– Giant axonal neuropathy is a severe neurodegenerative disorder of the peripheral and central nervous system that becomes clinically apparent in early childhood. Affected children present with a gait disturbance and frequent falls caused by muscle weakness and ataxia. A characteristic physical appearance is a hallmark; the hair tends to be red and tightly curled, the forehead high, the complexion pale, and eyelashes long. Progressive gait deterioration occurs, with death usually by the third decade. (See <a class="local">'Giant axonal neuropathy'</a> above.)</p><p></p><p class="headingAnchor" id="H1098829264"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert P Cruse, DO, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968; 18:603.</a></li><li><a class="nounderline abstract_t">Fridman V, Murphy SM. The spectrum of axonopathies: from CMT2 to HSP. Neurology 2014; 83:580.</a></li><li><a class="nounderline abstract_t">Klein CJ, Middha S, Duan X, et al. Application of whole exome sequencing in undiagnosed inherited polyneuropathies. J Neurol Neurosurg Psychiatry 2014; 85:1265.</a></li><li><a class="nounderline abstract_t">Liu YT, Laurá M, Hersheson J, et al. Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy. Neurology 2014; 83:612.</a></li><li><a class="nounderline abstract_t">Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22.</a></li><li><a class="nounderline abstract_t">Benquey T, Pion E, Cossée M, et al. A National French Consensus on Gene List for the Diagnosis of Charcot-Marie-Tooth Disease and Related Disorders Using Next-Generation Sequencing. Genes (Basel) 2022; 13.</a></li><li><a class="nounderline abstract_t">Mladenovic J, Milic Rasic V, Keckarevic Markovic M, et al. Epidemiology of Charcot-Marie-Tooth disease in the population of Belgrade, Serbia. Neuroepidemiology 2011; 36:177.</a></li><li><a class="nounderline abstract_t">Marttila M, Kytövuori L, Helisalmi S, et al. Molecular Epidemiology of Charcot-Marie-Tooth Disease in Northern Ostrobothnia, Finland: A Population-Based Study. Neuroepidemiology 2017; 49:34.</a></li><li><a class="nounderline abstract_t">Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002; 52:429.</a></li><li><a class="nounderline abstract_t">Attarian S, Fatehi F, Rajabally YA, Pareyson D. Hereditary neuropathy with liability to pressure palsies. J Neurol 2020; 267:2198.</a></li><li><a class="nounderline abstract_t">van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 2011; 7:315.</a></li><li><a class="nounderline abstract_t">Schwartzlow C, Kazamel M. Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification. Curr Neurol Neurosci Rep 2019; 19:52.</a></li><li class="breakAll">Kuhlenbäumer G, Timmerman V. Giant axonal neuropathy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1136/ (Accessed on December 07, 2011).</li><li><a class="nounderline abstract_t">Johnson-Kerner BL, Roth L, Greene JP, et al. Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis. Muscle Nerve 2014; 50:467.</a></li><li><a class="nounderline abstract_t">Takebe Y, Koide N, Takahashi G. Giant axonal neuropathy: report of two siblings with endocrinological and histological studies. Neuropediatrics 1981; 12:392.</a></li><li><a class="nounderline abstract_t">Ben Hamida C, Cavalier L, Belal S, et al. Homozygosity mapping of giant axonal neuropathy gene to chromosome 16q24.1. Neurogenetics 1997; 1:129.</a></li><li><a class="nounderline abstract_t">Bomont P, Cavalier L, Blondeau F, et al. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet 2000; 26:370.</a></li><li><a class="nounderline abstract_t">Flanigan KM, Crawford TO, Griffin JW, et al. Localization of the giant axonal neuropathy gene to chromosome 16q24. Ann Neurol 1998; 43:143.</a></li><li><a class="nounderline abstract_t">Mohri I, Taniike M, Yoshikawa H, et al. A case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments. Brain Dev 1998; 20:594.</a></li><li><a class="nounderline abstract_t">Mussche S, De Paepe B, Smet J, et al. Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms. Muscle Nerve 2012; 46:246.</a></li><li><a class="nounderline abstract_t">Demir E, Bomont P, Erdem S, et al. Giant axonal neuropathy: clinical and genetic study in six cases. J Neurol Neurosurg Psychiatry 2005; 76:825.</a></li><li><a class="nounderline abstract_t">Incecik F, Herguner OM, Ceylaner S, et al. Giant axonal disease: Report of eight cases. Brain Dev 2015; 37:803.</a></li><li><a class="nounderline abstract_t">Dooley JM, Oshima Y, Becker LE, Murphy EG. Clinical progression of giant-axonal neuropathy over a twelve year period. Can J Neurol Sci 1981; 8:321.</a></li><li><a class="nounderline abstract_t">Majnemer A, Rosenblatt B, Watters G, Andermann F. Giant axonal neuropathy: central abnormalities demonstrated by evoked potentials. Ann Neurol 1986; 19:394.</a></li><li><a class="nounderline abstract_t">Bharucha-Goebel DX, Norato G, Saade D, et al. Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort. Brain 2021; 144:3239.</a></li><li><a class="nounderline abstract_t">Carpenter S, Karpati G, Andermann F, Gold R. Giant axonal neuropathy. A clinically and morphologically distinct neurological disease. Arch Neurol 1974; 31:312.</a></li><li><a class="nounderline abstract_t">Treiber-Held S, Budjarjo-Welim H, Reimann D, et al. Giant axonal neuropathy: a generalized disorder of intermediate filaments with longitudinal grooves in the hair. Neuropediatrics 1994; 25:89.</a></li></ol></div><div id="topicVersionRevision">Topic 6207 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4297451" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008393" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The spectrum of axonopathies: from CMT2 to HSP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604904" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Application of whole exome sequencing in undiagnosed inherited polyneuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25008398" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280073" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Charcot-Marie-Tooth disease subtypes and genetic testing strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35205364" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A National French Consensus on Gene List for the Diagnosis of Charcot-Marie-Tooth Disease and Related Disorders Using Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546779" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of Charcot-Marie-Tooth disease in the population of Belgrade, Serbia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28810241" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular Epidemiology of Charcot-Marie-Tooth Disease in Northern Ostrobothnia, Finland: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12325071" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30989370" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hereditary neuropathy with liability to pressure palsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556032" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical and pathophysiological concepts of neuralgic amyotrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222456" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31222456" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hereditary Sensory and Autonomic Neuropathies: Adding More to the Classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947478" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801537" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Giant axonal neuropathy: report of two siblings with endocrinological and histological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10732815" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Homozygosity mapping of giant axonal neuropathy gene to chromosome 16q24.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11062483" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9450783" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Localization of the giant axonal neuropathy gene to chromosome 16q24.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865543" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806374" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Proteomic analysis in giant axonal neuropathy: new insights into disease mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897506" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Giant axonal neuropathy: clinical and genetic study in six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533284" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Giant axonal disease: Report of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7326612" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical progression of giant-axonal neuropathy over a twelve year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010802" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Giant axonal neuropathy: central abnormalities demonstrated by evoked potentials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114613" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Giant axonal neuropathy: cross-sectional analysis of a large natural history cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4153361" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Giant axonal neuropathy. A clinically and morphologically distinct neurological disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072681" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Giant axonal neuropathy: a generalized disorder of intermediate filaments with longitudinal grooves in the hair.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
